drugset / Trial / NCT00674453

The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

NCT00674453

Phase 2 Completed 51 enrolled Ligand Pharmaceuticals
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.

Timeline

Start
2004-09
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lasofoxifene Small molecule 0.25 mg Oral

Indications